The Center for Image Guided Neurosurgery, UPMC, Pittsburgh, Pennsylvania, USA.
Neurosurg Focus. 2012 Sep;33(3):E8. doi: 10.3171/2012.6.FOCUS12192.
Management recommendations for patients with smaller-volume or newly diagnosed vestibular schwannomas (< 4 cm(3)) need to be based on an understanding of the anticipated natural history of the tumor and the side effects it produces. The natural history can then be compared with the risks and benefits of therapeutic intervention using a minimally invasive strategy such as stereotactic radiosurgery (SRS).
The authors reviewed the emerging literature stemming from recent recommendations to "wait and scan" (observation) and compared this strategy with published outcomes after early intervention using SRS or results from matched cohort studies of resection and SRS.
Various retrospective studies indicate that vestibular schwannomas grow at a rate of 0-3.9 mm per year and double in volume between 1.65 and 4.4 years. Stereotactic radiosurgery arrests growth in up to 98% of patients when studied at intervals of 10-15 years. Most patients who select "wait and scan" note gradually decreasing hearing function leading to the loss of useful hearing by 5 years. In contrast, current studies indicate that 3-5 years after Gamma Knife surgery, 61%-80% of patients maintain useful hearing (speech discrimination score > 50%, pure tone average < 50).
Based on published data on both volume and hearing preservation for both strategies, the authors devised a management recommendation for patients with small vestibular schwannomas. When resection is not chosen by the patient, the authors believe that early SRS intervention, in contrast to observation, results in long-term tumor control and improved rates of hearing preservation.
对于体积较小或新诊断的前庭神经鞘瘤(<4cm³)患者,其管理建议需要基于对肿瘤预期自然病程及其产生的副作用的理解。然后,可以将自然病史与采用立体定向放射外科(SRS)等微创策略进行治疗干预的风险和获益进行比较。
作者回顾了最近关于“等待和扫描(观察)”的建议所产生的新文献,并将这种策略与 SRS 早期干预的发表结果或 SRS 与切除术的匹配队列研究的结果进行了比较。
各种回顾性研究表明,前庭神经鞘瘤的生长速度为每年 0-3.9mm,体积在 1.65-4.4 年内翻一番。在间隔 10-15 年的时间内进行研究时,SRS 可使高达 98%的患者肿瘤停止生长。大多数选择“等待和扫描”的患者注意到听力功能逐渐下降,导致 5 年内有用听力丧失。相比之下,目前的研究表明,在伽玛刀手术后 3-5 年内,61%-80%的患者保持有用听力(言语辨别评分>50%,纯音平均<50%)。
基于两种策略的体积和听力保护的已发表数据,作者为小体积前庭神经鞘瘤患者制定了管理建议。如果患者不选择切除术,作者认为早期 SRS 干预与观察相比,可实现长期肿瘤控制和提高听力保护率。